Download PDF
Zentralbl Chir 2014; 139(2): 175-183
DOI: 10.1055/s-0033-1350669
Übersicht
Georg Thieme Verlag KG Stuttgart · New York

Hepatozelluläres Karzinom – Aktuelles zu Screening, Surveillance und Therapiestrategien (aktualisierte EASL-EORTC-Empfehlungen)

Hepatocellular Carcinoma – Current Aspects of Screening, Surveillance and Therapeutic Strategies (Revised EASL-EORTC Recommendations)
E. Roeb
Medizinische Klinik und Poliklinik II, Schwerpunkt Gastroenterologie, Universitätsklinikum Gießen, Deutschland
› Author Affiliations
Further Information

Publication History

Publication Date:
16 October 2013 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Das hepatozelluläre Karzinom (HCC) gehört mit 523 000 neuen Fällen pro Jahr zu den häufigsten Krebsentitäten weltweit. In den letzten Jahren haben sich sowohl hinsichtlich der Diagnostik als auch in Bezug auf die therapeutischen Optionen deutliche Verbesserungen ergeben. Die Überwachung von Risikopatienten führt zu einer frühzeitigeren Diagnose kleiner HCCs. Nach wie vor ist eine frühe Diagnose die beste Voraussetzung für ein kuratives Therapiekonzept. Die vorliegende Übersichtsarbeit fasst die aktuellen Leitlinien der European Association for the Study of the Liver (EASL) und der European Organisation for Research and Treatment of Cancer (EORTC) unter besondere Berücksichtigung des Screenings und der Surveillance von Risikogruppen für das HCC zusammen.

Abstract

With an incidence of 523 000 new cases a year hepatocellular carcinomas (HCCs) belong to the most frequent cancer entities worldwide. Diagnostic and therapeutic procederes have been improved during the last years. Surveillance of patients with high risk factors leads to an early diagnosis. Up to now the detection of early HCCs represents the best prerequisite for any curative therapy. The present synopsis summarises the current guidelines of the European Association for the Study of the Liver (EASL) and the European Organisation for Research and Treatment of Cancer (EORTC) with a special focus on screening and surveillance of risk groups.

Schlüsselwörter

hepatozelluläres Karzinom - Lebertumor - multimodale Therapie

Key words

hepatocellular carcinoma - liver tumour - multimodal treatment
 

  • Literatur

  • 1 European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012; 56: 908-943
    CrossrefPubMedGoogle Scholar
  • 2 National Cancer Institute. PDQ_ levels of evidence for adult and pediatric cancer treatment studies. Bethesda, MD: National Cancer Institute. Date last modified 06/January/2013. Im Internet:. http://cancer.gov/cancertopics/pdq/levelsevidence-adult-treatment/healthprofessional/ Stand: 26.08.2010
    PubMedGoogle Scholar
  • 3 Parkin DM, Bray F, Ferlay J et al. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108
    Google Scholar
  • 4 International Agency for Research on Cancer (IARC). CancerMondial. Im Internet:. http://www-dep.iarc.fr/ Stand: 11.01.2013
    PubMedGoogle Scholar
  • 5 El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-750
    CrossrefPubMedGoogle Scholar
  • 6 Tanaka H, Imai Y, Hiramatsu N et al. Declining incidence of hepatocellular carcinoma in Osaka, Japan from 1990 to 2003. Ann Intern Med 2008; 148: 820-826
    CrossrefPubMedGoogle Scholar
  • 7 Bosetti C, Boffetta P, Lucchini F et al. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology 2008; 48: 137-145
    CrossrefPubMedGoogle Scholar
  • 8 Jemal A, Siegel R, Ward E et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71-96
    CrossrefPubMedGoogle Scholar
  • 9 Erhardt A, Zhu E, Blondin D et al. [Increasing number and improved survival of patients with hepatocellular carcinoma from 1988 to 2007: data of a German university clinic]. Z Gastroenterol 2011; 49: 720-727
    Article in Thieme ConnectPubMedGoogle Scholar
  • 10 Chang MH, You SL, Chen CJ et al. Decreased incidence of hepatocellular carcinoma in hepatitis B vaccinees: a 20-year follow-up study. J Natl Cancer Inst 2009; 101: 1348-1355
    CrossrefPubMedGoogle Scholar
  • 11 Sangiovanni A, Prati GM, Fasani P et al. The natural history of compensated cirrhosis due to hepatitis C virus: a 17-year cohort study of 214 patients. Hepatology 2006; 43: 1303-1310
    CrossrefPubMedGoogle Scholar
  • 12 Ioannou G, Splan M, Weiss N et al. Incidence and predictors of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol 2007; 5: 938-945
    CrossrefPubMedGoogle Scholar
  • 13 Masuzaki R, Tateishi R, Yoshida H et al. Prospective risk assessment for hepatocellular carcinoma development in patients with chronic hepatitis C by transient elastography. Hepatology 2009; 49: 1954-1961
    CrossrefPubMedGoogle Scholar
  • 14 Jung KS, Kim SU, Ahn SH et al. Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology 2011; 53: 885-894
    CrossrefPubMedGoogle Scholar
  • 15 Lok AS, Seeff LB, Morgan TR et al. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology 2009; 136: 138-148
    CrossrefPubMedGoogle Scholar
  • 16 Yang HI, Lu SN, Liaw YF et al. Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002; 347: 168-174
    CrossrefPubMedGoogle Scholar
  • 17 Chen CJ, Yang HI, Su J et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73
    CrossrefPubMedGoogle Scholar
  • 18 Iloeje UH, Yang HI, Su J et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
    CrossrefPubMedGoogle Scholar
  • 19 Raimondi S, Bruno S, Mondelli MU et al. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: a meta-analysis. J Hepatol 2009; 50: 1142-1154
    CrossrefPubMedGoogle Scholar
  • 20 Hsu IC, Metcalf RA, Sun T et al. Mutational hotspot in the p 53 gene in human hepatocellular carcinomas. Nature 1991; 350: 427-428
    CrossrefPubMedGoogle Scholar
  • 21 Deugnier YM, Guyader D, Crantock L et al. Primary liver cancer in genetic hemochromatosis: a clinical, pathological, and pathogenetic study of 54 cases. Gastroenterology 1993; 104: 228-234
    PubMedGoogle Scholar
  • 22 Perlmutter DH. Pathogenesis of chronic liver injury and hepatocellular carcinoma in alpha-1-antitrypsin deficiency. Pediatr Res 2006; 60: 233-238
    CrossrefPubMedGoogle Scholar
  • 23 Polio J, Enriquez RE, Chow A et al. Hepatocellular carcinoma in Wilsonʼs disease. Case report and review of the literature. J Clin Gastroenterol 1989; 11: 220-224
    CrossrefPubMedGoogle Scholar
  • 24 Marrero JA, Fontana RJ, Fu S et al. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. J Hepatol 2005; 42: 218-224
    PubMedGoogle Scholar
  • 25 Roeb E. [NASH (Non-Alcoholic Steatohepatitis): Fatty Liver or Fatal Liver Disease?]. Zentralbl Chir 2012; Mar 22. [Epub ahead of print]
    PubMedGoogle Scholar
  • 26 Trichopoulos D, Bamia C, Lagiou P et al. Hepatocellular carcinoma risk factors and disease burden in a European cohort: a nested case–control study. J Natl Cancer Inst 2011; 103: 1686-1695
    CrossrefPubMedGoogle Scholar
  • 27 Marcellin P, Pequignot F, Delarocque-Astagneau E et al. Mortality related to chronic hepatitis B and chronic hepatitis C in France: evidence for the role of HIV coinfection and alcohol consumption. J Hepatol 2008; 48: 200-207
    CrossrefPubMedGoogle Scholar
  • 28 Tanabe KK, Lemoine A, Finkelstein DM et al. Epidermal growth factor gene functional polymorphism and the risk of hepatocellular carcinoma in patients with cirrhosis. JAMA 2008; 299: 53-60
    CrossrefPubMedGoogle Scholar
  • 29 Abu Dayyeh BK, Yang M, Fuchs BC et al. A functional polymorphism in the epidermal growth factor gene is associated with risk for hepatocellular carcinoma. Gastroenterology 2011; 141: 141-149
    CrossrefPubMedGoogle Scholar
  • 30 Sarasin FP, Giostra E, Hadengue A. Cost-effectiveness of screening for detection of small hepatocellular carcinoma in western patients with Child-Pugh class A cirrhosis. Am J Med 1996; 101: 422-434
    CrossrefPubMedGoogle Scholar
  • 31 Fattovich G, Stroffolini T, Zagni I et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004; 127 (Suppl. 01) S35-S50
    CrossrefPubMedGoogle Scholar
  • 32 Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-1022
    CrossrefPubMedGoogle Scholar
  • 33 Di Bisceglie AM. Issues in screening and surveillance for hepatocellular carcinoma. Gastroenterology 2004; 127 (Suppl. 01) S104-S107
    CrossrefPubMedGoogle Scholar
  • 34 Martínez SM, Crespo G, Navasa M et al. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335
    CrossrefPubMedGoogle Scholar
  • 35 Craxì A, Cammà C. Prevention of hepatocellular carcinoma. Clin Liver Dis 2005; 9: 329-346
    CrossrefPubMedGoogle Scholar
  • 36 Bruno S, Stroffolini T, Colombo M et al. Italian Association of the Study of the Liver Disease (AISF). Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study. Hepatology 2007; 45: 579-587
    CrossrefPubMedGoogle Scholar
  • 37 Sung JJ, Tsoi KK, Wong VW et al. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28: 1067-1077
    CrossrefPubMedGoogle Scholar
  • 38 Lampertico P, Viganò M, Manenti E et al. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451
    CrossrefPubMedGoogle Scholar
  • 39 Bolondi L. Screening for hepatocellular carcinoma in cirrhosis. J Hepatol 2003; 39: 1076-1084
    CrossrefPubMedGoogle Scholar
  • 40 Kim CK, Lim JH, Lee WJ. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 2001; 20: 99-104
    CrossrefPubMedGoogle Scholar
  • 41 Barreiros AP, Piscaglia F, Dietrich CF. Contrast enhanced ultrasound for the diagnosis of hepatocellular carcinoma (HCC): comments on AASLD guidelines. J Hepatol 2012; 57: 930-932
    CrossrefPubMedGoogle Scholar
  • 42 Singal A, Volk ML, Waljee A et al. Meta-analysis: surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47
    CrossrefPubMedGoogle Scholar
  • 43 Sato T, Tateishi R, Yoshida H et al. Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C. Hepatol Int 2009; 3: 544-550
    CrossrefPubMedGoogle Scholar
  • 44 Bolondi L, Gaiani S, Celli N et al. Characterization of small nodules in cirrhosis by assessment of vascularity: the problem of hypovascular hepatocellular carcinoma. Hepatology 2005; 42: 27-34
    CrossrefPubMedGoogle Scholar
  • 45 Pateron D, Ganne N, Trinchet JC et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20: 65-71
    CrossrefPubMedGoogle Scholar
  • 46 Santi V, Trevisani F, Gramenzi A et al. Italian Liver Cancer (ITA.LI.CA) Group. Semiannual surveillance is superior to annual surveillance for the detection of early hepatocellular carcinoma and patient survival. J Hepatol 2010; 53: 291-297
    CrossrefPubMedGoogle Scholar
  • 47 Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 2008; 48 (Suppl. 01) S20-S37
    PubMedGoogle Scholar
  • 48 International Consensus Group for Hepatocellular Neoplasia. Pathologic diagnosis of early hepatocellular carcinoma: a report of the international consensus group for hepatocellular neoplasia. Hepatology 2009; 49: 658-664
    CrossrefPubMedGoogle Scholar
  • 49 Neeff H, Makowiec F, Harder J et al. [Hepatic resection for hepatocellular carcinoma–results and analysis of the current literature]. Zentralbl Chir 2009; 134: 127-135
    Article in Thieme ConnectPubMedGoogle Scholar
  • 50 Mazzaferro V, Battiston C, Perrone S et al. Radiofrequency ablation of small hepatocellular carcinoma in cirrhotic patients awaiting liver transplantation: a prospective study. Ann Surg 2004; 240: 900-909
    CrossrefPubMedGoogle Scholar
  • 51 Lu DS, Yu NC, Raman SS et al. Percutaneous radiofrequency ablation of hepatocellular carcinoma as a bridge to liver transplantation. Hepatology 2005; 41: 1130-1137
    CrossrefPubMedGoogle Scholar
  • 52 Majno PE, Adam R, Bismuth H et al. Influence of preoperative transarterial lipiodol chemoembolization on resection and transplantation for hepatocellular carcinoma in patients with cirrhosis. Ann Surg 1997; 226: 688-701
    CrossrefPubMedGoogle Scholar
  • 53 Czymek R, Gebhard M, Lubienski A et al. Intrahepatische Ablation: Radiofrequenzablation versus Elektrochemische Lyse. Zentralbl Chir 2011; 136: 379-385
    Article in Thieme ConnectPubMedGoogle Scholar
  • 54 Arguedas MR, Chen VK, Eloubeidi MA et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 2003; 98: 679-690
    CrossrefPubMedGoogle Scholar
  • 55 Lin OS, Keeffe EB, Sanders GD et al. Cost-effectiveness of screening for hepatocellular carcinoma in patients with cirrhosis due to chronic hepatitis C. Aliment Pharmacol Ther 2004; 19: 1159-1172
    CrossrefPubMedGoogle Scholar
  • 56 Zhang BH, Yang BH, Tang ZY. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 2004; 130: 417-422
    PubMedGoogle Scholar
  • 57 Trevisani F, De Notariis S, Rapaccini G et al. Semiannual and annual surveillance of cirrhotic patients for hepatocellular carcinoma: effects on cancer stage and patient survival (Italian experience). Am J Gastroenterol 2002; 97: 734-744
    CrossrefPubMedGoogle Scholar
  • 58 Bolondi L, Sofia S, Siringo S et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001; 48: 251-259
    CrossrefPubMedGoogle Scholar